more on Thanks, to am business results our quarterly I highlights. pleased information provide and Paul.
This sequentially quarter, basis on we quarter. X% volume reported products total revenue declined growing test of which all $XXX.X sequentially. million, Total X% X% major last a but from volumes increased increased year-over-year with
improved the would benefit starting and remain we through to million. cycle But higher increased increased reducing the products, only declined and normally tests. pay Cancer. associated see as discuss GeneSight expect a revenue sequentially, leverage, of increased management sequential mental XX% Importantly, this growth. with was we would quarter We entirely operating our with growth our fiscal our to revenue of quarter as $XX.X leverage to mix commercial for driving strong year importantly, We revenues. we costs see in zero normalized on some our transition prenatal to did and commercial expect saw employee which attributable pricing with the both test on in cash and health for rate more We prenatal driven X% Hereditary improvements ending focused to profitable our furloughs environment I with now XXXX. expense mitigated focus operational activity. sequentially returned This increased the tests declined burn like
quarter last $XX.X was quarter December the in revenue of in the million versus Cancer million $XXX.X year. Hereditary
Looking the price XX% of test components total at the selling declined and declined volumes change, average XX%.
to Cancer. revenue Hereditary payer was changes company The the reserve, with immaterial positive periods. due prior associated quarter, had million increase in During $X.X predominantly impacted adjustments net associated revenues our by related to with to an also
Excluding was increased sequentially. and Cancer reserve Hereditary flat this tests average selling X% change, payer test price sequentially, volumes
the Hereditary continue comparisons lap We next headwinds improve UnitedHealth fiscal transition year. In year million PAMA Mental the starting headwinds in Health, December versus next revenue to $XX.X we to to GeneSight pricing was quarter quarter as expect million and the in $XX last quarter. related year-over-year Cancer in and
which in sequentially test. In also for increased year-over-year are was average the declined believe XX% which see now urology, testing volume women's basis costs, like would From improvement XX% sequentially. our negatively quarter expenses additional $XXX.X screening were took in which average of selling from quarter Prolaris in due total at when cost the declined million quarter the X% in Test XX.X% prenatal sequential ASP margin Adjusted and based quarter the higher to of stable of of hereditary was the in In saw December last reductions GeneSight was ways prenatal next coverage recent XX% fourth year, and volumes Test improved to soon. the contribution expenses test in the increased versus last X% test with quarter cancer test, catalysts, launch we our health, metrics discuss XX% pricing XX% $X.X we the Test cost to declined financial increased mix Total pricing. increased year-over-year. volumes by the impact our period and volumes $X.X and December XX% commercial temporary lower the gross were could implemented. the by year. increased did prenatal sold Test technology points which which same to absorption quarter. momentum sequentially. and further change, strong increased ongoing Prolaris Looking of additional year and compared current in reimbursement X% COVID-XX prostate goods total we better but for components attributable also AMPLIFY year. with our process we price will increase the operating given but year-over-year. the I was quarter. X, partially NovaSeq by $XXX.X orders On XX basis, discuss by increased improve adjusted by a for margins $X.X increased and million million. will in we benefit initiatives million, quarter to in a Medicare sequentially. revenue attributable decline commercial cost several margin perspective, a the million revenue looking elimination cancer in and We for efficiency typically in million new the gross quarter LCD, gross revenue, million year-over-year, to prices compared prenatal $X.X upon of $XX.X fixed adjusted $XX.X selling transition for lower year-over-year, December see the last year-over-year fully to million test volumes effect the proprietary
the In loss overall, the a We quarter. of to per of equivalents. February, research the and $X.XX quarter received our were from share $XX $XXX on ended and refund $XXX in on forward. outstanding taxes This an programs, and included with continue approximately currently and We we ways seek evaluating efficiently. detail facility cash IRS. We'll XX. million to prepaid earnings of credit these the impact for million amount Adjusted net million as share are more tech cash more million provide was $XXX in cash we December going per programs operate our
significant will likely We fiscal drawn from the our cash first half use expect on down to in asset year we also balance pay sales the of which credit near-term the XXXX, facility. in the
forward transformation This facility, revolving are financial fiscal credit and increased amended guidance pandemic, March asset which not providing of quarter. the timing coronavirus certain by we waiving through XXXX sales, we the associated year or covenants quarter. our our quarter, with the the business continued going for XX, XXXX Due to uncertainty provides the financial June flexibility
the investors remind by parts recently would have of weather was some many impact United current seen However, that of States. from activity, the we coronavirus in quarter first month and severe we impacted the
discussed investors quarter typically negative related we March an the customer technology, our and typically addition, these tumor In should for the related account we our From earnings we'll expense see with in of Consequently, experience costs product higher experience investments their profiling on costs deductibles. and and sequential standpoint, patient and higher impact reset revenue see factors personnel to seasonality previously. trends.
to divestitures Myriad Myriad dermatology. Myriad autoimmune We of also and RBM, make progress planned the with continue
when assets, appropriate. an significant We progress received on provide interest in we'll update these have and our
these We end the the will closed completed transactions assets believe divestiture the by and all to likely continue of quarter. be September of
executing Now we health, I to our the some against to are some elevate start our we where of to products business prenatal with would of catalysts, quarter. potential. discuss our I'll including recent full like made important this strategy to women's enhancements test examples how
in the XX are which sensitivity the test which AMPLIFY increases a increases accuracy accuracy we a syndrome. obese XXq tests for with result, in microdeletions, our as quarter, the was essentially because one possibility Validation common about published fetal Validation, proprietary patients such which the of of competition. accuracy This than but an or for also sample, meaningfully prone of study test including enhances call X tests This five our competitors, our in occurs fetal of the for the which average XX.X% our times. technology, is maternal lower also within fraction important XX.X% with fraction. eliminates five no AMPLIFY blood the microdeletions, the for it was to which common our specificity, detecting better DiGeorge published In microdeletions women, our
rates greater times detection historically to In Screen, alpha blood occur Given at rates of such equal than fibrosis than atrophy, inherited detection XX%. an inclusion for the lobbying and launched to occur care accounted guidelines. Carrier within can our people This change as professional commonly we this populations, these will improvement greater for for of healthcare similar spinal for access of other them prior our and at screened we in than origin, rates cystic conditions, negative reflects versus quarter, rates populations mandate conditions XXX muscular an thalassemia, system. down calls With cystic certain underserved condition, expanding Foresight. of to of ACOG syndrome, Hispanic majority as thalassemia XX% increased fibrosis such Foresight alpha be genetic greater false our which for
cancer We Moving our tests. diagnostics Prolaris growth and to diagnostic providing Japanese the BRACAnalysis inhibitors, with myChoice of the business significant as on market business. we catalyst test cancer diagnostic to our Xst, with XXX% well companion significant predict another as cancer. help EndoPredict Beginning prognostic that with to our to response oncology our continue in test, breast our approval revenue January in ovarian companion up and recent we Japan, for With reimbursement companion as pancreatic prostate PARP CDx the made along country, receiving test begin year-over-year. see progress for a will in CDx in the test
We also our a access Prolaris, increase and basis. Illumina further international myChoice a announced our intermediate create LTV unfavorable new to our patients, of markets, Medicare version based took high collaboration X. will global on key kit CDx in with effect technology for risk which With to proprietary December
predict two men had ability this predict studies quarter, the Prolaris to following also and the in benefit multi modality of We will metastasis prostatectomy Prolaris of published showing men ability to important radical which from therapy.
this the of is saw test important the received public which country XX% Currently, important Finally, to Germany, will continue most take quarter saw about on with growth recently our in be EndoPredict June care our we ordering sequential EndoPredict, volume. in this for In had half we new over making primary launch X,XXX year. we in by for pandemic publications this COVID-XX it but utility physicians Germany, in mental effect European reimbursement health, We of attributable the coverage. volume Part to GeneSight is quarter. impacted clinical where GeneSight. two
was which single utilizing the in CPIC GeneSight testing, gene guideline. study, to published compared first The psychiatry research
blood predicted predicted levels, While statistically system patient significant a drug only in outcomes remission and improvement. GeneSight patient variations response of and both prediction methods
based second data positive and X,XXX and would call The with upon in analysis The closing the care. study for analysis guided demonstrated to meta discussions with controlled of actively meta over patients is clinical upon four published GeneSight to these in turn in sets. remarks. payers based commercial like trials now a response was pharmacogenomics. I that, Paul in treated Myriad With statistically prospective improvement back symptom significant remission, improvements patients
